Bluto Blutarsky
Footballguy
Let’s get Golf Daughter registered here
But we know leronlimab is completely safe. 800 people have taken it for HIV for years with zero SAEs. There were a lot of SAEs in the M2M trial. Those SAEs must have been caused by Covid. The treatment arm having less SAEs would imply efficacy.She said she they did a cancer study on brain cancer. They injected the drug into the brain and it killed the cancer but also killed the person. So it was a good drug for cancer but not safe at all
Was it dissinfectant? And was Trump running the surgery?She said she they did a cancer study on brain cancer. They injected the drug into the brain and it killed the cancer but also killed the person. So it was a good drug for cancer but not safe at all
this was my first thought also.Reply from my daughter. One reason to stall is if they are waiting to get listed on NASDAQ. This could be because good or bad results. To get that protection before releasing info so the stock can not be manipulated as easy.
Both sides of the trial have a lot of SAEs. The SAEs being caused by Covid is the only explanation.There is no direct correlation between SAE numbers. They need to be studied on a case by case basis. SAE can have nothing to do with the drug.
No on a whole. Needs to be determined case by case to get true numbers. SAE can be someone on LL has a heart attack while taking LL when LL had nothing to do with the attack.But we know leronlimab is completely safe. 800 people have taken it for HIV for years with zero SAEs. There were a lot of SAEs in the M2M trial. Those SAEs must have been caused by Covid. The treatment arm having less SAEs would imply efficacy.
It's a 14 day trial. Each arm having 5 or 8 SAEs is not random stuff. It has to be caused by Covid. No other explanation makes sense.No on a whole. Needs to be determined case by case to get true numbers. SAE can be someone on LL has a heart attack while taking LL when LL had nothing to do with the attack.
SAE can also have nothing to do with Covid.There is no direct correlation between SAE numbers. They need to be studied on a case by case basis. SAE can have nothing to do with the drug.
Most likely. Placebo's cause insignificant harm, and LL has been shown to be extremely safe. Most of the SAE's in this trial are likely from Covid.Both sides of the trial have a lot of SAEs. The SAEs being caused by Covid is the only explanation.
In a small sample size, you just cant say this. More often than not you may be right. This is science and results need to be scrutinized.It's a 28 day trial. Each arm having 5 or 8 SAEs is not random stuff. It has to be caused by Covid. No other explanation makes sense.
That's true. You could get hit by a car or have something else happen to you. But if the drug and the placebo are completely safe, then there is a good chance that the SAE is being caused by Covid.SAE can also have nothing to do with Covid.
84 people. 14 days. 13 SAEs and they aren't Covid related?In a small sample size, you just cant say this. More often than not you may be right. This is science and results need to be scrutinized.
Is it a good sign? Yes. Is it empirical evidence. No.Most likely. Placebo's cause insignificant harm, and LL has been shown to be extremely safe. Most of the SAE's in this trial are likely from Covid.
We will find out. How you want drug studies to work isn't how they work.84 people. 14 days. 13 SAEs and they aren't Covid related?
I don't disagree but it means squat to the FDA.That's true. You could get hit by a car or have something else happen to you. But if the drug and the placebo are completely safe, then there is a good chance that the SAE is being caused by Covid.
Of course. It has yet to be determined. People are just speculating. This was the only study done on Covid so far, where the drug beat the placebo in SAE count.Is it a good sign? Yes. Is it empirical evidence. No.
Thanks. I'll tell my wife.One last thing she said. Old drugs are still doing good stuff all the time. Being old has no relevance.
Is it hitting 7?You selling any Monday?
I talked with her on the phone about this. It's a good marker but she just wont make the leap you guys are because she knows it is not directly related.Most likely. Placebo's cause insignificant harm, and LL has been shown to be extremely safe. Most of the SAE's in this trial are likely from Covid.
Their primary outcome measure was a decrease in their symptoms score. Then they had 12 secondary outcomes and 4 exploratory outcomes. She said they are throwing darts at everything.Text from wife.
She's on the clinical trials.gov. She's reading about their M2M study
It's not necessarily directly related but since the placebo cannot cause SAEs directly and leronlimab does not cause SAEs it is reasonable to assume that all SAEs were caused by Covid? And since the treatment arm had less SAEs than the placebo arm, leronlimab is the reason?I talked with her on the phone about this. It's a good marker but she just make the leap you guys are because she knows it is not directly related.
So is a delay in top line results still worrisome?Their primary outcome measure was a decrease in their symptoms score. Then they had 12 secondary outcomes and 4 exploratory outcomes. She said they are throwing darts at everything.
The request itself is worrisome. Too broad IHO.So is a delay in top line results still worrisome?
Correlation does not equal causation.It's not necessarily directly related but since the placebo cannot cause SAEs directly and leronlimab does not cause SAEs it is reasonable to assume that all SAEs were caused by Covid? And since the treatment arm had less SAEs than the placebo arm, leronlimab is the reason?
Doesn’t make much sense as the disease isn’t well known nor the mechanism for how the drug would affect it. If you’re doing a study, why not introduce many measures to get a good idea of how your drug affects people as it pertains to Covid? These parameters were set early March when even less was known. They were set in partnership with the FDA.The request itself is worrisome. Too broad IHO.
There is a total of 19 SAEs. The study had 84 patients over 14 days. It is probably all Covid. Maybe 1 is not. But probably all are Covid.She said a person on one of her studies got in a car accident and was hospitalized that was a SAE. She had one in hospital with appendicitis that was a SAE. One was in the hospital or a gall bladder surgery that was a SAE. None of them were drug related.
They can not say it was Covid
Re didn't say it was bad to have so many secondary causes. She thinks they are hoping to show it works on many different areasDoesn’t make much sense as the disease isn’t well known nor the mechanism for how the drug would affect it. If you’re doing a study, why not introduce many measures to get a good idea of how your drug affects people as it pertains to Covid? These parameters were set early March when even less was known. They were set in partnership with the FDA.
Except for the one person who died who appartently was a Leronlimab patient.But we know leronlimab is completely safe. 800 people have taken it for HIV for years with zero SAEs. There were a lot of SAEs in the M2M trial. Those SAEs must have been caused by Covid. The treatment arm having less SAEs would imply efficacy.
I took a look at the Remdesivir study to get a comparison. In her opinion was the primary outcomes for Remdesivir "better" from a trial structure viewpoint? Does CYDY investigation outcomes differ that much?She thinks having 16 secondary outcomes is going to take a while to analyze but they all ready know if they hit their primary or not. Don't know why they are not telling that info.
They’ll get killed if they release just the primary and then nothing else imo. Would make sense to me to wait till you have it all.She thinks having 16 secondary outcomes is going to take a while to analyze but they all ready know if they hit their primary or not. Don't know why they are not telling that info.
Where did you get this? Thought we didn't know what group the patient was in?Except for the one person who died who appartently was a Leronlimab patient.
Who said that?Except for the one person who died who appartently was a Leronlimab patient.
I agree with this. If there were ever a trial where you’d throw every dart it would be this one.Doesn’t make much sense as the disease isn’t well known nor the mechanism for how the drug would affect it. If you’re doing a study, why not introduce many measures to get a good idea of how your drug affects people as it pertains to Covid? These parameters were set early March when even less was known. They were set in partnership with the FDA.
Process of elimination by omission.Where did you get this? Thought we didn't know what group the patient was in?Except for the one person who died who appartently was a Leronlimab patient.
Also releasing just part of this would lead to more skepticism. Where is the rest of the report? Must have been terrible if they just released a part of it? If you want the true stock pop you need to put it all out. Once people analyzed it, they would drag it down.She thinks having 16 secondary outcomes is going to take a while to analyze but they all ready know if they hit their primary or not. Don't know why they are not telling that info.
Who said that?
From the company website.Of the 84 patients treated, one patient died 33 days after enrollment due to an event unrelated to leronlimab.
I think Nader said the patient died 33 days after the trial started and they were in the treatment arm. And then he said that a patient dying from a car accident would be considered as an SAE. But he was talking theoretical. Clearly, the patient died from Covid and was in the treatment arm.Where did you get this? Thought we didn't know what group the patient was in?
But it may not be drug related, it may be.Process of elimination by omission.
Yup. Doesn't look good when your only patient who dies from a mild/moderate case of Covid was taking the cure.I think Nader said the patient died 33 days after the trial started and they were in the treatment arm. And then he said that a patient dying from a car accident would be considered as an SAE. But he was talking theoretical. Clearly, the patient died from Covid and was in the treatment arm.
Should be crickets and minor price movements until the efficacy report is published and/or the uplisting. Good for some day trading but not much to opine about.Buncha slow, old fogies around here these days.
![]()